EUVIMED · CrossrefJournal
The Brown University Psychopharmacology Update
ISSN 1068-5308 · Wiley
Latest articles
Study finds GLP‐1 RAs reduced 4‐year mortality by 24% compared to SGLT2 inhibitors in people with SMI
Meta‐analysis shows rapid relapse after antipsychotic discontinuation linked to baseline severity, not withdrawal
Antidepressant use during pregnancy benefits mothers with pre‐existing depression
Single‐dose psilocybin superior to placebo for MDD in community setting
Ketamine found safe and effective for treatment‐resistant bipolar depression in small trial
Pilot study supports broader research on psilocybin for anorexia nervosa
Menopausal hormone therapy may protect against Alzheimer's disease
Risks of lithium toxicity in patients taking ACEi or ARB medications no greater than those taking beta blockers: Cohort study
Aripiprazole associated with lower risk of hyponatremia than olanzapine
SGLT2 inhibitors improve kidney function in lithium‐treated patients
Buprenorphine‐naloxone after opioid withdrawal treatment reduces overdose risk
Single dose of psilocybin shows extended benefit in depression trial
Buprenorphine following ketamine treatment enhances anti‐suicidal effects
Adjunctive antipsychotics for MDD differ in efficacy and acceptability
New oral anticoagulants and related anxiety symptoms
Meta‐analysis finds ketamine infusions efficacious in treatment of depression
Trial suggests effectiveness of psilocybin for cocaine use disorder
Genotype‐guided SSRI prescribing might have long‐term benefit
Meta‐analysis suggests need for personalized dosing in ADHD treatment
Overprescribing and the ‘mental health crisis’: will deprescribing make America healthy again?
Approvals
Your Medication Information
Vaporized mebufotenin leads to improvement in treatment‐resistant depression
Semaglutide reduces drinking in adults with alcohol use disorder and obesity
Patterns of antidepressant use in elderly retirees
Phase 1 trial suggests benefit of psilocybin in OCD treatment
Mirtazapine reduces methamphetamine use in Phase 3 trial
Novel antipsychotic shows efficacy in Phase 2 schizophrenia trial
Benzodiazepine use in pregnancy not linked to risk of psychiatric disorders in children
Study suggests some patients can successfully resume clozapine after neutropenia
EUVIMED